Enzyme Development Corporation Overview
Enzyme Development Corporation is a niche, family-owned U.S. specialty enzyme company founded in 1953. It is headquartered in Manhattan, and its manufacturing, quality-control, regulatory and warehousing operations are in Scranton, Pennsylvania. Its main distinction is that it describes itself as the only papain producer in the Western Hemisphere. It also claims the same position for ficin and thistle rennet, giving it an unusual franchise in botanical (plant-derived) proteases at a time when food manufacturers increasingly want clean-label, non-GMO, vegan, kosher, halal and organic-compliant processing aids. Around this botanical core, EDC sells a broad catalogue of microbial carbohydrases, proteases, peptidases and lactases. These come from solid-state and submerged fermentation organisms (Aspergillus, Bacillus, Trichoderma, Rhizopus, Kluyveromyces) and are sold under the Enzeco®, Panol®, Liquipanol®, Enzobake®, Enzopharm®, Multizyme®, Adjuzyme®, Fresh-N® and Thistlezyme® brands. EDC competes on application expertise, custom blending, responsive service and certification breadth rather than scale. It serves flavour houses, pet food, meat, dairy, baking, brewing and distilling, starch processing, supplements and animal feed customers across the Americas, Europe and Asia.
The company's own description
EDC describes itself as a biotechnology company specialising in enzymes for food processing, animal feed, nutritional supplements, brewing and distilling. Its corporate office is in New York City and its factory is in Scranton (LinkedIn company page). The About page lists its value proposition as more than 70 years of experience in enzyme applications and formulation, consistent quality, an extensive product line, custom blending and packaging, and fast attention to customer requirements. The 2024 corporate press release calls it a family-owned business focused on enzymes for food, feed and industrial uses.
What the company does
EDC makes, standardises, blends, packages and sells enzyme preparations. These are biological catalysts used as processing aids or active ingredients. The company says it draws on two source types (Getting to Know EDC, July 2021):
Botanical enzymes extracted from plants: papain from papaya latex sourced from smallholder farmers in Africa and Asia; bromelain from pineapple stems; ficin from tropical fig latex; and Thistlezyme® aspartic protease from Cynara cardunculus flowers from Portugal.
Microbial enzymes produced by fermentation: solid-state fermentation (e.g., Aspergillus oryzae, A. niger) and submerged deep-tank fermentation (e.g., Bacillus amyloliquefaciens, Trichoderma reesei).
The Scranton plant carries out enzyme extraction and makes liquid and powdered preparations (New Hope Network). It runs more than 60 specialised enzyme assays, plus microbial, pathogen and metals testing (company website).
Business model and revenue model
Product sales: effectively all revenue appears to come from selling physical enzyme preparations in bulk, from single drums to dedicated truckloads (company website). There is no evidence of subscription, licensing or royalty income.
Hybrid manufacturer–distributor model: an older company description (reproduced by ZoomInfo) says EDC's own manufacturing and lab capabilities are supplemented by the research expertise of domestic and overseas manufacturers whose products EDC represents on an exclusive basis. This implies that part of the microbial catalogue is toll-produced or sourced from partners and then standardised, blended and sold by EDC. The split between own-produced and resold products is not publicly disclosed.
Embedded service element: technical sales staff with scientific backgrounds provide application support, custom blending and specification work. This is bundled into product pricing and not charged separately, as far as can be determined.
Pricing model: not publicly disclosed. B2B quote-based pricing by activity unit and volume is standard in this industry.
Value-chain position
EDC sits in the middle of the chain. Upstream are raw latex and plant material (papaya, pineapple, fig, thistle) and fermentation feedstocks or partner-made enzyme concentrates. EDC handles extraction, purification, standardisation on carriers such as maltodextrin, blending, QC and regulatory documentation. Downstream are industrial food, feed and supplement manufacturers. Some products are used as processing aids, which typically need no ingredient declaration. Others, such as supplement enzymes, are active ingredients.
Customer types and end-markets
| End-market | Representative uses (company-stated) |
|---|---|
| Flavour modification | Hydrolysed proteins, yeast extracts, enzyme-modified cheese (EMC), debittering |
| Pet food | Digest and palatant production, hairball treatments, pelleting |
| Meat & seafood | Tenderising (including fajita strips and clam), meat flavours, sausage casings |
| Dairy | Lactose-free milk, GOS, dulce de leche, cheesemaking (thistle rennet), EMC |
| Baking | Dough relaxation, crumb softness, shelf life (Fresh-N®), frozen dough proofing |
| Brewing & potable alcohol | Chill-haze reduction (papain), low-calorie beer, liquefaction, saccharification, sake |
| Starch processing | Maltodextrin, dextrose in corn wet milling, high-maltose syrups; 2026 push on proteases in wet milling |
| Food supplements / nutraceuticals | Digestive-aid enzymes (papain, bromelain, lactase, alpha-galactosidase, Enzopharm® Plus) |
| Animal feed & agriculture | Silage inoculants, feed enzymes, OMRI-listed organic feed enzymes |
| Juice, fruit & wine | Juice yield, removal of fermentation by-products |
| Other | Toothpaste, collagen and gelatin hydrolysis, peptide production, candy (invertase) |
The website and trade-directory listings show the following end-markets:
Historically the company also served detergent protease, textile/denim, and pulp and paper markets, having started in brewing enzymes (New Hope Network). Its largest food-related sales are reported to be in protein modification and enzymes for flavour production and processing. Sales are reported to be concentrated in the Americas and Pacific Rim (New Hope Network).
Independent characterisation
EDC is best described as a specialty botanical-protease house with a broad, partly sourced microbial catalogue. Its strategic value depends on three hard-to-replicate assets:
-
a Western Hemisphere papain, ficin and thistle-rennet production base;
-
certification breadth: OMRI organic, Kof-K kosher (including kosher-for-Passover papain), IFANCA halal, non-GMO, vegan-suitable and gluten-free-claim-compatible grades;
-
long-tenured application know-how.
Its weaknesses are sub-scale fermentation economics compared with global majors, reliance on tropical agricultural supply chains, and very small organisational depth.
Strategy
EDC publishes no annual report or investor day. Strategy is inferred from company communications.
Stated strategic themes (company communications, paraphrased):
-
Positioning as a customer-oriented, technically led enzyme partner that builds long-term relationships ("At EDC – Enzymes Are Our Business")
-
Exploiting its unique Western Hemisphere botanical protease production (papain, ficin, thistle rennet)
-
Clean-label innovation: the company cites recent work on organic-compliant certified enzymes, vegan-compliant enzymes and specialised flavour-releasing biocatalysts
Initiatives in the last 24 months (Oct 2024–Oct 2026):
Medium-term financial targets or guidance: not publicly disclosed. No cost programmes, ESG targets or transformation programmes have been announced.
Products & Services
Pricing is not publicly disclosed for any product. Launch years are given only where documented.
Botanical proteases (Family A)
| Product | Description & specification | Target customers / applications | Launch / version |
|---|---|---|---|
| Panol® | Powdered papain standardised to 100 and 300 MCU/mg | Supplements, meat, brewing, flavours, pet food | Long-standing |
| Liquipanol® | Liquid papain standardised to 100 and 200 TU/mg | Protein hydrolysis, brewing chill-proofing, meat | Long-standing |
| Liquipanol® RS 100 | Liquid papain processed without sulfites, 100 TU/mg | Clean-label and organic processing | — |
| Liquipanol® RS 400 | Liquid no-sulfite papain | Organic and clean-label hydrolysis | — |
| Enzeco® Purified Papain Concentrate | Concentrated papain powder | Supplement manufacturers | — |
| Enzeco® Purified Papain RS Concentrate | Papaya latex processed without sodium metabisulfite; much lower SO2; botanical enzyme only; OMRI Listed® | Organic food processing, organic animal feed, supplements | OMRI listings from 2014 |
| Enzeco® Purified Papain RS 600 | No-sulfite papain standardised to 600 TU/mg on maltodextrin | Supplements, hydrolysis | — |
| Enzeco® Dual Protease RS 150 | No-sulfite papain plus bromelain blend | Meat and clam tenderising | — |
| Enzeco® Bromelain | Purified pineapple-stem protease at multiple activity levels (CDU, MCU, FCC-PU, BTU) | Meat, flavours, baking, supplements, toothpaste, collagen hydrolysis, pet hairball treatments, pea/soy/whey hydrolysis | EDC active in bromelain since early 1970s |
| Enzeco® Ficin 100 | Fig-latex cysteine protease, 100 MCU/mg on IP maltodextrin; lower deactivation temperature than papain or bromelain; non-GMO, clean label | Meat tenderising (thin cuts such as fajita strips), protein hydrolysis combined with papain or bromelain | Sep 2020 |
| Ficin 250 BAPA/g | Higher-standardised ficin grade announced with Ficin 100 | Protein hydrolysis | Announced 2020 |
| Enzeco® Ficin Liquid 50K | First standardised liquid ficin; non-GMO, gluten-free, vegan-suitable, kosher and halal; GRAS | Plant-protein hydrolysis for meat alternatives, gelatin hydrolysis, EMC, milk/wheat/soy/pea/rice/oat proteins | Early 2024 |
| Enzeco® Ficin 50K (powder, flagged "NEW") | Ficin grade marketed for meat tenderising | Meat processors | Flagged new Feb 2026 |
| Thistlezyme® | Aspartic protease extracted and partly purified from Cynara cardunculus flowers (Portugal); true vegetarian rennet | Cheesemaking (ewe, goat, cow milk); also gluten hydrolysis; currently approved for dairy only | Not disclosed; dedicated site thistlerennet.com |
Microbial proteases & peptidases (Family B)
| Product | Source organism / specification | Applications |
|---|---|---|
| Enzeco® Fungal Protease MG | Non-GMO A. oryzae; strong endo-protease, lower exo-protease; powder or micro-granulate up to 1,000,000 HUT/g | Flavours, baking, meat, supplements, yeast cell-wall hydrolysis, EMC |
| Enzeco® Fungal Acid Protease | Non-GMO A. niger; pH optimum 2.5–3.5, usable up to pH 6.5; kosher/halal alternative to pepsin | Pepsin replacement, flavour, FAN release, supplements |
| Enzeco® Fungal Protease 400 | A. oryzae acid and alkaline protease blend with LAP, carboxypeptidase and neutral protease; debittering | Flavour-enhanced hydrolysed proteins, EMC, baking |
| Enzeco® Protease 400 WF | Same profile, fermented without wheat; suitable for "gluten-free" claims | Gluten-free hydrolysed proteins and flavours |
| Enzeco® Protease FNP | A. oryzae fungal neutral protease, pH 5–7, high aminopeptidase and acid carboxypeptidase; non-GMO multi-enzyme debittering complex | Flavour modification, protein hydrolysis |
| Enzeco® DPP | A. oryzae dipeptidyl aminopeptidase; used with or after another protease | Flavours, collagen hydrolysis |
| Enzeco® Peptidase AO-30 | A. oryzae exo-peptidase with debittering side activities | Flavours, EMC |
| Enzeco® Neutral Bacterial Protease 160S | B. amyloliquefaciens; pH 5.5–8; very low amylase | Flavours, meat, protein hydrolysis |
| Enzeco® Alkaline Protease L-660 | Non-GMO B. licheniformis endopeptidase with side activities | Pet-food digests, yeast hydrolysis, peptides |
Starch-hydrolysing carbohydrases (Family C)
| Product | Source / specification | Applications |
|---|---|---|
| Enzeco® Bacterial Alpha Amylase | Non-GMO B. amyloliquefaciens; moderately heat-stable; RAU assay | Starch liquefaction, supplements, brewing, baking, maltodextrin, pet-food pelleting, feed |
| Enzeco® Bacterial Amylase BL | Thermostable liquid alpha-amylase from B. licheniformis; optimum about 198°F | High-temperature liquefaction, brewing, feed |
| Enzeco® Bacterial Amylase 25LN | Liquid alpha-amylase, B. amyloliquefaciens | Liquefaction, maltodextrin, brewing |
| Enzeco® Bacterial Amylase 10k | Dry alpha-amylase with protease side activity | Cereal processing, baking, brewing |
| Enzeco® Fungal Alpha Amylase | A. oryzae; liquid and powder | High-maltose syrups (DE 40–45), baking, brewing, sweet potato |
| Fresh-N® | Heat-resistant bacterial alpha-amylase; with or without dedusting oil | Moisture, aroma and shelf-life extension in bread, cakes, cookies, brownies |
| Enzeco® Glucoamylase Powder RO | Non-GMO Rhizopus oryzae; hydrolyses alpha-1,4 and alpha-1,6 bonds | Corn wet-milling dextrose, low-cal beer, silage, sake |
| Enzeco® Glucoamylase Powder AN | A. niger, very pure; preservative-free for organic use | Lean/frozen dough proofing, brewing |
| Enzeco® Glucoamylase 400 | A. niger glucoamylase plus B. licheniformis pullulanase | Brewing, sweetness enhancement |
| Enzeco® Glucoamylase L 500 | Trichoderma reesei saccharifying glucoamylase | Brewing, potable alcohol |
| Adjuzyme® | Liquid A. niger exo-glucosidase | Brewing fermentable sugars |
| Multizyme® II | Fungal plus bacterial amylase blend with protease and beta-glucanase | Corn silage, animal feeds |
Non-starch carbohydrases (Family D)
| Product | Source / specification | Applications |
|---|---|---|
| Enzeco® Invertase | Saccharomyces cerevisiae; Sumner units | Soft-centre candy, invert syrup, supplements |
| Enzeco® Invertase AN | A. niger; pH 2.5–6, up to 70°C | Syrups, candy, baking |
| Enzeco® Fungal Lactase | Non-GMO A. oryzae acid-optimum beta-galactosidase; FCC ALU | Lactase tablets/capsules, dry mixes, yogurt, GOS |
| Enzeco® Lactase NL | Kluyveromyces yeast lactase; YLU | Lactose-free milk, dulce de leche, reduced-sugar dairy, GOS |
| Enzeco® Lactase KL | Highly concentrated, filterable Kluyveromyces lactase for Aldose/FlexDos dosing systems | Lactose-free milk |
| Enzeco® Alpha Galactosidase | Non-GMO A. niger; hydrolyses melibiose, stachyose, raffinose | Supplements (anti-flatulence), feed |
Blends (Family E) and other lines (Family F)
| Product | Description | Applications |
|---|---|---|
| Enzobake® | A. oryzae protease and amylase blend | Bread dough conditioning, volume, anti-staling |
| Enzopharm® Plus | Supplement blend: 23,500 SKB/g amylase; 58,000 HUT/g protease; 1.4 FIPU/mg lipase; 230 ACU/g hemicellulase; 1,750 FCC ALU/g lactase | Digestive-enzyme supplements |
| Septizyme® | Trade name listed in FoodMaster directory | — |
| Cellulases, lipases/esterases, pectinases, xylanases | Listed in Bloomberg profile | Juice, wine, feed, flavours |
Services
-
Custom blending and packaging
-
Technical application support from the technical sales team (company claims 90+ combined years of food and enzyme experience)
-
More than 60 enzyme activity assays, published assay methods (e.g., FCC-PU plant protease method), and regulatory documentation (kosher, halal, OMRI, non-GMO, GRAS)
Financial Narrative
No audited or management financial statements are publicly available. EDC is private and files nothing with the SEC. All tables below are left blank (not publicly disclosed) so that no figure is invented. The only external datapoints are third-party revenue estimates, shown separately.
Income statement
Revenue CAGR: not publicly disclosed.
Qualitative financial commentary
Without financials, trend analysis has to rely on operating signals.
Gross-margin drivers. Botanical enzymes depend on agricultural raw materials: papaya latex from smallholders in Africa and Asia, pineapple stems, fig latex, and Portuguese thistle. Their input costs are therefore exposed to crop yields, weather, logistics and FX. EDC's own blog post titled "So…You Got a Great Deal on Bromelain" suggests price competition in commodity bromelain. Value-added grades should carry premiums: no-sulfite OMRI papain, liquid ficin, and gluten-free-claim proteases.
Fixed-cost base. The business runs one plant in Scranton plus a small Manhattan office. Operating leverage is likely high, but scale is limited.
Capital intensity. No disclosed capex. The 1990s move to Scranton was the last documented major facility investment.
Signals of stability rather than distress. These include continued product launches (2020, 2024, 2026), new OMRI listings in 2024 and 2025, an orderly leadership succession (2024), trade-show presence (IPPE, Meat Conference, IFT 2026) and active content marketing in 2026. One aggregator (Nombase) labels the company "out of business", which is contradicted by the 2025–2026 OMRI listings, website activity and the 2026 IFT sponsorship. That label is treated as erroneous.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Analyst Product Family Details
| Analyst product family | Contents | Key brands |
|---|---|---|
A. Botanical proteases | Papain (powders, liquids, concentrates, no-sulfite/OMRI grades), bromelain, ficin, thistle rennet | Panol®, Liquipanol®, Enzeco® Purified Papain, Enzeco® Bromelain, Enzeco® Ficin, Thistlezyme® |
B. Microbial proteases & peptidases | Fungal (A. oryzae, A. niger) and bacterial (Bacillus) proteases; debittering peptidases; DPP | Enzeco® Fungal Protease, Protease FNP, 400 / 400 WF, DPP, Peptidase AO-30, Neutral Bacterial Protease 160S, Alkaline Protease L-660 |
C. Starch-hydrolysing carbohydrases | Bacterial and fungal alpha-amylases, glucoamylases, pullulanase blends | Enzeco® Bacterial Alpha Amylase, Amylase BL/25LN/10k, Fungal Alpha Amylase, Glucoamylase RO/AN/400/L 500, Adjuzyme®, Fresh-N® |
D. Non-starch carbohydrases | Invertases, lactases, alpha-galactosidase | Enzeco® Invertase, Invertase AN, Fungal Lactase, Lactase NL/KL, Alpha Galactosidase |
E. Blends & multi-enzyme systems | Baking, supplement and feed blends | Enzobake®, Enzopharm® Plus, Multizyme® II, Enzeco® Dual Protease RS 150, Septizyme® |
F. Other catalogue lines (not detailed in this research) | Cellulases, lipases/esterases, pectinases, xylanases | Listed by Bloomberg profile |
Provider Details
| Provider | Estimate | Date observed | Comment |
|---|---|---|---|
ZoomInfo | about USD 7.5M annual revenue | 2026 | Model-based estimate |
LeadIQ | USD 10–25M range | Mar 2026 | Model-based range |
Discrepancy | Estimates differ by up to about 3x | — | Neither verifiable; treat as order-of-magnitude only (single-digit to low-double-digit USD millions) |
Capital Markets
| Item | Status |
|---|---|
Share price performance (1/3/5-year) | Not applicable (private) |
Analyst consensus | None; no sell-side coverage |
Credit ratings (Moody's / S&P / Fitch) | None identified |
External funding | None recorded (Tracxn, Nombase) |
Capital markets metric (not applicable / not disclosed) | FY2021 |
Analyst Conclusions
Management guidance: none published.
Consensus growth expectations: none; no analyst coverage.
Bull case
-
Scarcity value of the botanical base. As the self-described only Western Hemisphere producer of papain, ficin and thistle rennet, EDC holds a supply-security asset that U.S. food, pet and supplement manufacturers value more when tariffs and logistics are unstable.
-
Clean-label tailwinds monetised through premium grades. No-sulfite OMRI papain, gluten-free-compatible proteases, vegan and halal/kosher ficin, and four new OMRI feed listings in 2024–2025 show an active pipeline into premium niches.
-
New application vectors: corn wet-milling proteases (as SO2 costs rise), plant-protein hydrolysis, meat tenderising and ruminant GHG enzymes could add volume without a new plant.
Bear case
-
Structural scale gap. Majors such as Novonesis grew 7% organically with a 37% adj. EBITDA margin in FY2025 and guide to 5–7% growth in 2026. EDC's microbial catalogue, partly sourced from partners, risks commoditisation.
-
Concentrated operational risk: one plant, a small team (aggregators estimate fewer than 50 people), and tropical agricultural inputs.
-
Low visibility and data noise: no disclosures, an aggregator wrongly flagging the company as "out of business", and dated web copy can hurt procurement qualification with large customers.
Key catalysts and monitorables (next 12 months)
-
Renewal of OMRI listings expiring 1 Dec 2026
-
Further ficin or Thistlezyme® launches, or regulatory approvals beyond dairy for Thistlezyme®
-
Commercial results from the corn wet-milling protease initiative
-
Any public progress on ruminant GHG enzymes
-
Changes in the Moodie advisory role or further leadership moves
-
Strategic approaches from consolidators, or any ownership change
-
Raw-material supply disruptions (papaya latex)
-
U.S. tariff changes on imported enzyme inputs
Analyst verdict
Enzyme Development Corporation is not the public company named in the input brief. It is a durable, family-owned niche specialist that has survived more than seven decades in an industry steadily consolidated by multinational biosolutions groups. Its defensibility does not come from scale, which it lacks; aggregator estimates put revenue between roughly USD 7.5M and USD 25M and headcount at about 18 to 50. It comes from a narrow but real asset: domestic production of botanical proteases (papain, ficin, thistle rennet) that the company says no other Western Hemisphere producer makes. That base is complemented by unusually broad certification coverage and long-tenured application expertise across flavours, pet food, meat, dairy, baking, brewing, starch and supplements.
The evidence since 2020 points to a company in steady, low-key renewal rather than decline. It launched Ficin 100 in 2020 and Ficin Liquid 50K in 2024, and flagged a new ficin grade in 2026. It added OMRI feed listings in 2024 and 2025, completed an orderly presidential succession in January 2024, and is visibly pursuing adjacent markets such as corn wet milling and ruminant emissions.
The central strategic tension is that its microbial enzyme lines, likely the larger share of its catalogue, compete head-on with far better-capitalised majors. Its botanical lines are exposed to tropical supply and to price competition from Asian producers. A single plant and a thin management bench add operational fragility.
For counterparties, EDC looks like a credible, specialised supplier, best used for botanical proteases, certified clean-label grades and custom technical work rather than high-volume commodity enzymes. For acquirers, it is a plausible bolt-on whose main value is its papain/ficin/thistle know-how and certifications. Absolute financial conclusions are not possible: no audited financials, segment data or ownership details are public, and any valuation or credit view would need direct due diligence.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure / background | Source |
|---|---|---|---|
Wallace Chavkin | Chief Executive Officer / key principal (per D&B) | Tenure, age and education not publicly disclosed. Whether he is a member of the owning family is not confirmed. | D&B |
Brian Murdoch | President (since 1 Jan 2024) | Previously Vice President of EDC; extensive experience in fermentation and industrial enzyme applications; handles day-to-day management | Company press release; Pet Food Processing; Food Business News |
Peter Moodie | Senior Management Advisor (since 1 Jan 2024) | Joined EDC in 1987; President 2010–2023; IFT member since 1976; now leads longer-term growth projects | Company press release; IFT Food Technology |
Christina Barsa | Director, Strategic Accounts (per FoodMaster); LeadIQ lists a "C. B." as Vice President (Mar 2026), likely the same person, unconfirmed | Author of corporate web content | FoodMaster; LeadIQ; company website |
Andrea Dreyfus | Laboratory / QC Laboratory Manager | Presented an IFT poster comparing ficin, papain and bromelain | Company blog; LeadIQ |
David Drasdauksas | General Manager, Scranton | Key principal for the Scranton site | D&B; Buzzfile |
Competitive Landscape
Key Competitors
| Competitor | Segment overlap with EDC | Ownership | Relative positioning | Verified datapoints (source) |
|---|---|---|---|---|
Novonesis (Novozymes + Chr. Hansen) | Microbial carbohydrases and proteases; dairy (lactase); brewing; baking; feed | Public (Copenhagen) | Global leader; vastly larger | FY2025 organic sales growth 7%; adj. EBITDA margin 37.1%; FY2026 guidance 5–7% organic growth (Novonesis, Feb 2026) |
IFF (former Genencor / DuPont N&B) | Food, brewing, baking, starch enzymes | Public (NYSE) | Global major | — |
dsm-firmenich | Dairy, baking, brewing enzymes | Public (Euronext) | Global major | — |
AB Enzymes (ABF Ingredients) | Baking, food, feed enzymes | Subsidiary of Associated British Foods | Large specialist | — |
Amano Enzyme | Food and supplement enzymes, proteases, lactase | Private (Japan) | Strong in supplements and flavour | — |
Kerry Group (incl. Biosearch / enzymes) | Food and pharma enzymes, bromelain/papain | Public (Euronext Dublin) | Taste and nutrition major | — |
Advanced Enzyme Technologies | Supplement, food and feed enzymes, including botanical proteases | Public (NSE/BSE, India) | Low-cost Asian specialist | — |
BIO-CAT | Food and supplement enzymes | Private (USA) | U.S. specialty peer | — |
Biocatalysts Ltd (BRAIN Biotech) | Flavour/protein hydrolysis specialty enzymes | Subsidiary of BRAIN Biotech (public) | Specialty flavour peer | — |
Specialty Enzymes & Probiotics; Deerland; National Enzyme Co. | Supplement enzymes | Private | U.S. supplement-channel competitors | — |
Creative Enzymes | Lipase and food enzymes | Private | Named alongside EDC in lipase food-enzyme market coverage | ZoomInfo news headline |
VTR Biotech | Feed enzymes | Public (SZSE: 300381) | Expanding into the EU and Latin America (Brazil subsidiary set up in 2026) | Wikipedia (Apr 2026) |
Fornia BioSolutions; American Biosystems; Ultreze Enzymes | Various enzymes | Private | Listed by Crunchbase as alternatives | Crunchbase |
Asian and African papain/bromelain producers (various) | Commodity papain and bromelain | Mostly private | Price competition in botanical proteases | EDC blog implies bromelain price pressure |
Peer Comparison FY2025
| Metric | EDC | Novonesis |
|---|---|---|
FY2025 revenue | Not disclosed (estimates about USD 7.5M or USD 10–25M) | — |
FY2025 organic growth | — | 7% |
FY2025 adj. EBITDA margin | — | 37.1% |
Western Hemisphere papain production | Yes (sole producer, company claim) | No |
“—” = not publicly disclosed.
Recent Developments
Not identified in the period: * contract wins, guidance revisions, litigation, regulatory actions, restructurings, layoffs or acquisitions.



